A phase 1/2 trial of PTT-4256 in advanced solid tumours, run by Pathios Therapeutics Pty Ltd, now recruiting.
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1). is a phase 1/2 interventional study registered as NCT06634849 by Pathios Therapeutics Pty Ltd, with 30 participants planned, started 2024-11-04 and due to reach its primary completion in 2027-04-30. Interventions recorded: PTT-4256.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.